Pharmaceutical Investment Oversight and Accountability Act
A bill to require the Federal Trade Commission to submit a report on foreign investment in the pharmaceutical industry of the United States, and for other purposes.
This bill, SB4987, aims to have the Federal Trade Commission (FTC) compile and submit a report on foreign investment in the U.S. pharmaceutical industry. The goal is to understand how foreign investments might affect the industry and, by extension, the availability and cost of medicines for American consumers. The report would also consider implications for jobs and innovation in the sector.
Those affected by this bill include pharmaceutical companies, investors, and consumers. The FTC's findings could influence future regulations on foreign investment in the U.S. pharmaceutical market. This may have implications for both domestic and international stakeholders within the industry.
SB4987 was introduced on July 15, 2026, and subsequently referred to the Senate Committee on Banking, Housing, and Urban Affairs. As of July 15, 2026, the bill is in its initial stages, having been read twice and referred to the appropriate committee for further consideration. No further actions have been recorded at this time.
